Table 1.
References | Study | Year | Sample size | Antithrombotic regimena | Populationb | Average follow-up (months) | Age (mean) | Male (%) | HT (%) | HL (%) | CSM (%) | HSM (%) | CAD (%) | CVD (%) | DM (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
[36] | Becquemin | 1997 | 243 | P vs TP2 | PVI | 24 | 67 | 77 | 51 | 25 | 22 | 23 | 24 | ||
[15] | BOA | 2000 | 2690 | A vs VKA2 | PVI | 21 | 69 | 64 | |||||||
[37] | CABBAGE | 2017 | 50 | A vs A+CI | PVI | 3 | 73 | 74 | 88 | 50 | 14 | 40 | 54 | 26 | 74 |
[13] | CAPRIE | 1996 | 6452 | A vs C | PAD | 23 | 64 | 72 | 51 | 45 | 38 | 90 | 54 | 14 | 21 |
[38] | CASPAR | 2010 | 851 | A vs A+C | PVI | 12 | 66 | 76 | 70 | 50 | 38 | 35 | 37 | ||
[39] | CHARISMA | 2009 | 3096 | A vs A+C | PAD | 26 | 60 | 70 | 72 | 70 | 32 | 85 | 25 | 16 | 36 |
[40] | CLIPS | 2007 | 366 | A vs P | PAD | 21 | 66 | 77 | 62 | 26 | 80 | 76 | |||
[16] + [41] | COMPASS | 2018 | 7470 | A vs A+R1 vs R2 | PAD | 21 | 68 | 72 | 79 | 28 | 75 | 65 | 7 | 45 | |
[42] | COOPER | 2012 | 431 | C vs TP1 | PAD | 3 | 71 | 88 | 74 | 56 | 25 | 88 | 13 | 18 | 33 |
[33] | CREDO | 2006 | 272 | A vs A+C | CAD | 12 | 67 | 66 | 76 | 74 | 30 | 100 | 32 | ||
[44] | ePAD | 2018 | 203 | A+C vs A+E | PVI | 2.7 | 67 | 29 | 83 | 35 | 86 | 40 | |||
[35] | EUCLID | 2017 | 13,885 | C vs TG2 | PAD | 30 | 66 | 72 | 78 | 76 | 31 | 78 | 29 | 12 | 39 |
[45] | Gresele | 2000 | 159 | A vs A+CC | PAD | 6 | 66 | 86 | 45 | 64 | 84 | 25 | |||
[46] | Johnson | 2002 | 831 | A vs A+VKA1 | PVI | 38 | 64 | 88 | 25 | 17 | 36 | ||||
[47] | Li | 2013 | 50 | C vs C+VKA1 | PVI | 12 | 74 | 66 | 70 | 24 | 51 | 59 | 20 | 42 | |
[48] | MIRROR | 2011 | 80 | A vs A+C | PVI | 6 | 70 | 53 | 78 | 63 | 40 | 33 | 19 | 38 | |
[49] | Monaco | 2012 | 318 | A+C vs C+VKA1 | PVI | 77 | 67 | 70 | 81 | 24 | 61 | 48 | |||
[50] | PEGASUS TIMI 54 | 2016 | 1143 | A vs A+TG1 vs A+TG2 | CAD | 36 | 66 | 78 | 85 | 81 | 30 | 100 | 3 | 42 | |
[51] | PLATO | 2015 | 1144 | A+C vs A+TG2 | CAD | 9 | 66 | 75 | 79 | 66 | 38 | 74 | 100 | 15 | 38 |
[52] | RIVAL-PAD | 2020 | 20 | A+C vs A+R1 | PVI | 3 | 67 | 60 | 0 | 0 | |||||
[53] | Soga | 2009 | 80 | A+TP1 vs A+TP1+CI | PVI | 24 | 71 | 83 | 49 | 33 | 39 | 54 | 9 | [36 | |
[54] | STOP-IC | 2013 | 200 | A vs A+CI | PVI | 12 | 73 | 59 | 81 | 47 | 461 | 39 | 56 | ||
[17] | VOYAGER-PAD | 2020 | 6564 | A vs A+R1 | PVI | 28 | 67 | 74 | 81 | 60 | 35 | 32 | 40 | ||
[55] | WAVE | 2007 | 2161 | A vs A+ VKA1 | PAD | 35 | 64 | 74 | 58 | 29 | 39 | 47 | 16 | 27 |
CAD coronary artery disease, CSM current smoker, CVD cerebrovascular disease, DM diabetes mellitus, HL hyperlipidaemia, HSM history of smoking, HT hypertension, INR international normalized ratio
aAntithrombotic regimen: A acetylsalicylic acid 75–325 mg daily, C clopidogrel 75 mg once daily, CC cloricromene 100 mg twice daily, CI cilostazol 200 mg once daily, E edoxaban 60 mg once daily, P placebo only, R1 rivaroxaban 2.5 mg twice daily, R2 rivaroxaban 5 mg twice daily, TG1 ticagrelor 60 mg twice daily, TG2 ticagrelor 90 mg twice daily, TP1 ticlopidine 200 mg twice daily, TP2 ticlopidine 250 mg twice daily, VKA1 vitamin K antagonist with target INR between 1.4 and 3, VKA2 vitamin K antagonist with target INR between 3 and 4.5
bPopulation: CAD studies on patients with coronary artery disease who coincide with peripheral arterial disease, PAD studies on patients who are solely selected for peripheral arterial disease, PVI studies on patients who underwent a peripheral vascular intervention for peripheral arterial disease